With new PhI­II da­ta in hand, Der­ma­vant lines up top­i­cal pso­ri­a­sis con­tender for a sprint to the fin­ish line

With new PhI­II da­ta in hand, Der­ma­vant lines up top­i­cal pso­ri­a­sis con­tender for a sprint to the fin­ish line

Submitted by admin on April 23, 2021 - 11:09am
Source: 
Endpoints
News Tags: 
Dermavant
psoriasis
tapinarof
clinical trials
Headline: 
With new PhI­II da­ta in hand, Der­ma­vant lines up top­i­cal pso­ri­a­sis con­tender for a sprint to the fin­ish line
snippet: 

In the next couple months, Dermavant CEO Todd Zavodnick says he’ll sprint to the FDA with tapinarof, the company’s “cosmetically elegant” vanishing cream to treat psoriasis. But before that, he has more Phase III data to share.

Do Not Allow Advertisers to Use My Personal information